Valence 로고
인기
로그인
Loading data for PTGX — first visit, this takes a few seconds.

관심목록에 추가

Protagonist Therapeutics ...

NasdaqGM: PTGX · 실시간 가격 · USD
154.94
-2.40 (-1.53%)
종가 기준: Aug 17, 2026, 8:00 PM
158.75
+0.08%
애프터마켓: 7:34 PM

Protagonist Therapeutics Inc. (PTGX) Stock Price, Analysis & Data

-1.53%

데이터 없음

매수호가97.79
시가총액10.26B
매출 (ttm)281.99M
순이익 (ttm)82.91M
베타1.79
EPS (ttm)1.02
P/E (ttm)151.07
선행 P/E-1134.46
P/B (ttm)12.19
P/S (ttm)36.40
Earnings DateNov 5, 2026
매도호가175.12
거래량757,935
평균 거래량 (20일)682,195
시가159.99
전일 종가157.34
일중 범위154.22 - 160.81
52주 범위54.50 - 160.81
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

PTGX 소개

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare b...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Aug 11, 2016
직원 수 141
상장 거래소 NasdaqGM
티커 PTGX
웹사이트 https://www.protagonist-inc.com
전체 기업 정보

재무 실적

2025년 Protagonist Therapeutics의 매출은 46.02M로, 전년 434.43M 대비 -89.41% 감소했습니다. 순이익은 -130.15M로, -147.29% 감소했습니다.

재무제표

어닝 서프라이즈

Protagonist Therapeutics가 Aug 5, 2026에 분기 실적을 발표했습니다:
  • 매출 $213.47M 예상치 하회 $0, 및 3749.17% 전년 대비 성장.
  • EPS 2.29 예상치 상회 0.36, 및 516.36% 전년 대비 성장.

    • 다음 실적 발표

    Protagonist Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1주 전 · BioPharma Dive

    Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

    Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels n...

    news image

    1주 전 · MT Newswires

    Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

    Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activ

    news image

    1주 전 · Zacks

    4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

    PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

    news image

    1주 전 · Zacks

    Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

    Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    news image

    2주 전 · Zacks

    Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

    Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +8.53% and -3.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock...

    2 페이지 중 1